Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Neuroleptic malignant syndrome

What is neuroleptic malignant syndrome?

Neuroleptic malignant syndrome is a rare and life-threatening reaction to neuroleptic use. It is generally characterised by muscular rigidity, tremor, fever, autonomic nervous system dysfunction, and alterations in level of consciousness. It may become apparent soon after commencing antipsychotic use or when dose is increased and should be treated as a medical emergency.

What is the evidence on neuroleptic malignant syndrome?

Moderate to low quality evidence is unable to determine the prevalence of neuroleptic malignant syndrome with any particular antipsychotic use. The one review included in this topic describes 140 cases that were induced with second generation antipsychotic use, and authors conclude that second generation antipsychotics are not free of the risk of neuroleptic malignant syndrome.

November 2019

Last updated at: 1:51 am, 25th November 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.